NCT04991077Completed
Interrupters of VAscular daMAge in Malignant Hypertension
Interrupters of VAscular daMAge in Malignant Hypertension: Role of Inflammasome, Angiogenic and Vasoactive System
Source: ClinicalTrials.gov · Last updated 30 Oct 2024
Brief summary (registry, in English)
The pathophysiology of malignant hypertension is poorly understood. The objective of this translational research project is to evaluate the relationship between activation of vasoactive systems (renin-angiotensin and endothelin systems), angiogenic signal deficiency (VEGF and sFlt-1) and the occurrence of malignant hypertension episodes in humans.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 45 (actual)
- First submitted
- 16 Jun 2021
- Start date
- 7 Feb 2022
- Primary completion date
- 11 Oct 2024
- Lead sponsor
- Centre Hospitalier de PAU
- Diseases
- High blood pressure
- NCT number
- NCT04991077
What you commit to
- Study type: Observational
- Participants enrolled: 45
- From 7 Feb 2022 to the primary completion date, 11 Oct 2024
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with chronic renal failure of stage 3 or higher.
- Patients with any type of diabetes
- Evidence of subacute involvement of one of the following target organs: brain, kidney, eye, heart, thrombotic microangiopathy. Target organ impairment is defined in the inclusion criteria for the "Patients" group.
- Presence of known chronic kidney insufficiency of grade 3 or higher
- Diabetes of any type
Age
- Age \< 18 years old
Other
- Patients group :
- Patient in per partum
- Patients who cannot freely give their consent, or patients who refuse to participate
- Chronic dialysis patient
- Control group:
- Chronic dialysis patient
- Patients who cannot freely give their consent, or patients who refuse to participate
Who the study is looking for
- Patients group :
- Patients included in the HAMA cohort
- Who is willing to take part in the IVAMA project
- Control group :
- Grade 2 or 3 hypertension with office blood pressure measurement (above 160 and/or 100 mmHg for systolic and diastolic)
- Persistence of blood pressure above 160 / 100 mmHg on the average of 3 "attended" blood pressure measurements
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Avicenne Coordinator of this site? Confirm its status | Bobigny | France | Unknown status |
| CHU de Bordeaux Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| Hôpital Bichat Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Hôpital Européen Georges Pompidou Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Hôpital Tenon Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| CHU Rangueil Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
| CHU de Tours Coordinator of this site? Confirm its status | Tours | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.